Aesthetic Medical International Holdings Group (PAIYY) AI Stock Analysis

• Market Cap: $8.28M
• Dividend Yield: N/A
• Average Volume (3M): 576.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.19
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1,286
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 48,687,584
• 10 Day Avg. Volume: 50
• 30 Day Avg. Volume: 576
• PEG Ratio: 0.04
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 0.05
• P/FCF Ratio: 0.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $0.29 ▲(72.94% Upside)

The overall stock score of 53 reflects the company's ongoing challenges in achieving profitability and managing debt, despite improvements in revenue growth and cash flow. Technical indicators show positive momentum, but the lack of valuation metrics limits a comprehensive assessment of the stock's value.

Positive Factors

Revenue Growth

The company's consistent revenue growth indicates a strong market position and increasing demand for its aesthetic services, which is crucial for long-term success.

Cash Flow Improvement

Improved cash flow suggests better financial management and operational efficiency, enhancing the company's ability to invest in growth opportunities.

Market Demand

Growing consumer interest in aesthetic treatments supports long-term revenue potential, positioning the company to benefit from favorable industry trends.

Negative Factors

High Leverage

High leverage can limit financial flexibility and increase risk, potentially impacting the company's ability to navigate economic downturns.

Profitability Challenges

Persistent profitability issues highlight the need for effective cost management and operational improvements to ensure long-term financial health.

Low Equity Ratio

A low equity ratio suggests vulnerability to financial instability, necessitating efforts to strengthen the equity base for sustainable growth.

Aesthetic Medical International Holdings Group Business Overview & Revenue Model

Company Description

Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in the People's Republic of China and Singapore. The company offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments, including minimally invasive and energy-based treatments, which include laser, ultrasound, and radiofrequency treatments. It also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. The company was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.

How the Company Makes Money

The company generates revenue primarily through its aesthetic medical services offered at its clinics. This includes fees from various non-invasive procedures and treatments that clients seek for cosmetic enhancements. Additionally, PAIYY earns income from the sale of aesthetic medical devices and products, which are either developed in-house or sourced from partnerships with other manufacturers. The company may also benefit from strategic alliances or collaborations with other healthcare providers, enhancing its service offerings and expanding its market reach. Through these diversified revenue streams, PAIYY capitalizes on the increasing consumer interest in aesthetic treatments, contributing significantly to its overall earnings.

Aesthetic Medical International Holdings Group Financial Statement Overview

Summary

Aesthetic Medical International Holdings Group is making strides towards improvement, with notable revenue growth and better cash flow management. Nevertheless, profitability remains elusive, and the balance sheet's leverage presents risks. Continued focus on reducing debt and enhancing profitability is essential for future stability.

Income Statement

The company has shown improvement in reducing its operating losses, with EBIT rising from -48.81 million to -4.04 million. Revenue growth is evident with a 10.7% increase from the previous year. However, the net profit margin remains negative, indicating ongoing challenges in achieving profitability. Continued focus on cost management is needed.

Balance Sheet

The company's financial stability is concerning, with a high debt-to-equity ratio due to significant liabilities overshadowing the small equity base. The equity ratio is low at 6.3%, indicating heavy reliance on debt financing. However, there have been improvements in stockholders' equity and asset management, which is a positive sign.

Cash Flow

The cash flow situation has improved, with a positive free cash flow growing significantly from the previous year. The operating cash flow is healthy and exceeds net income, indicating strong cash generation capabilities despite net losses. Continued improvement in free cash flow sustainability is crucial.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	755.67M	682.59M	670.09M	645.59M	901.57M
Gross Profit	337.79M	322.05M	355.59M	269.50M	544.78M
EBITDA	73.33M	25.31M	-11.05M	-554.95M	-123.90M
Net Income	-19.95M	-37.43M	-76.25M	-586.62M	-235.48M
Balance Sheet
Total Assets	486.22M	560.66M	546.37M	576.94M	1.04B
Cash, Cash Equivalents and Short-Term Investments	42.84M	62.34M	12.16M	39.29M	44.38M
Total Debt	179.30M	244.55M	393.10M	405.91M	460.79M
Total Liabilities	476.88M	527.03M	672.25M	763.36M	612.35M
Stockholders Equity	30.46M	48.89M	-113.66M	-156.67M	390.90M
Cash Flow
Free Cash Flow	48.88M	18.83M	-76.80M	17.65M	-46.01M
Operating Cash Flow	79.67M	74.29M	-75.13M	51.09M	-843.00K
Investing Cash Flow	-30.32M	-52.25M	3.11M	-11.53M	-127.37M
Financing Cash Flow	-68.55M	29.06M	45.55M	-45.23M	17.70M

Aesthetic Medical International Holdings Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAIYY, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.20, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.01 is Neutral, neither overbought nor oversold. The STOCH value of 6.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAIYY.

Aesthetic Medical International Holdings Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	63 Neutral	$6.52M	38.04	5.90%	―	-4.99%	-19.11%
PAIYY	53 Neutral	$8.28M	―	-76.57%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HSCS	41 Neutral	$7.07M	―	-193.24%	―	-66.40%	65.99%
TNMG	39 Underperform	$8.15M	-0.09	-164.27%	―	4.59%	-920.35%
NCNA	28 Underperform	$16.52M	―	-179.40%	―	―	94.52%